SCHEMBL334104

SCHEMBL334104

COC(=O)c1ccc(-c2c(C(=O)OC)c3cc(Oc4ccc(Cl)c(Cl)c4)ccc3n2-c2ccc(OC(C)C)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 3/20 0.42
BCL2 P10415 2/20 0.42
MCL1 Q07820 2/20 0.42
MAPT P10636 6/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
HPGD P15428 3/20 0.40
MAPK1 P28482 2/20 0.40
HTT P42858 2/20 0.40
PKM P14618 2/20 0.40
ALOX15 P16050 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 1/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 3/20 0.38
GAA P10253 1/20 0.37
MGLL Q99685 1/20 0.36
PTGES O14684 1/20 0.36
POLB P06746 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL333633 0.92 BCL2 (0.44) MDM2BCL2MCL1MAPTSMN1; SMN2
SCHEMBL335545 0.89 MDM2 (0.44) MDM2BCL2MCL1MAPTSMN1; SMN2
SCHEMBL334015 0.88 KMT2A (0.43) MDM2BCL2MCL1HPGDMEN1
SCHEMBL333981 0.87 MDM2 (0.44) MDM2BCL2MCL1MAPTSMN1; SMN2
SCHEMBL333729 0.87 MAPT (0.54) MDM2BCL2MCL1MAPTSMN1; SMN2
SCHEMBL333553 0.80 USP14 (0.45) MDM2BCL2MCL1HPGDMEN1
SCHEMBL333886 0.78 RXRA (0.45) MDM2BCL2MCL1KMT2AKDM4E
SCHEMBL27717567 0.77 PPARG (0.41) MDM2BCL2MCL1MAPTSMN1; SMN2
SCHEMBL333957 0.75 MAPT (0.42) MAPTSMN1; SMN2HPGDMAPK1HTT
SCHEMBL333544 0.74 PTGES (0.45) MDM2BCL2MCL1KMT2APTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG MDM2 917/4885BCL2 325/4885MCL1 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.